Co-evolutionary dynamics of viral pathogens and human antibody response
- Funded by European Commission
- Total publications:0 publications
Grant number: 101224126
Grant search
Key facts
Disease
COVID-19, UnspecifiedStart & end year
20262032Known Financial Commitments (USD)
$11,804,996.46Funder
European CommissionPrincipal Investigator
N/A
Research Location
GermanyLead Research Institution
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRSResearch Priority Alignment
N/A
Research Category
N/A
Research Subcategory
N/A
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
N/A
Abstract
Vertebrates, like ourselves, use adaptive immune cells to protect themselves from pathogens. Predicting mutations of these pathogens, together with the immune response, is essential for the design of vaccines and therapies. CoEvolve will map the co-evolution of immune repertoires and viral populations, to forecast likely properties of future infecting strains and to design interventions that improve immune control. Much effort has been devoted to evolving viral pathogens, but most studies focus either on viral evolution or on immune adaptation in individual hosts. Yet pathogen and host dynamics are coupled: viruses escape from immune recognition, while immune systems adapt to changing viruses. CoEvolve takes an integrative approach: we will study host immune evolution and viral evolution together and on equal footing. We will focus on two viruses, influenza and SARS-CoV-2, that cause severe respiratory diseases. Both viruses evolve rapidly and are transmitted between hosts in acute infections. Influenza has evolved in humans over decades, while SARS-CoV-2 has entered humans more recently and is likely reaching a long-term co-evolutionary state. In both systems, we will track and predict co-evolution on multiple scales: in laboratory experiments, longitudinal human tracking studies, and globally circulating populations. CoEvolve will develop new molecular binding and neutralisation assays for high-throughput tracking of host-pathogen immune interactions and multi-scale inference methods for coevolution. Based on these data and methods, we will • map co-evolutionary landscapes of viral-immune molecular interactions, • build data-driven models of human immunity and co-evolutionary dynamics, • predict viral-immune co-evolution and inform vaccination strategies to optimize immune control. CoEvolve addresses a fundamental science problem, to understand host-pathogen co-evolution from its molecular basis, and will break ground towards improved public health interventions.